Latest Content

The approval is based on findings from the phase 3 SCOUT-HCM trial.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.

A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.